Organization
Foundation Medicine, Inc., Cambridge, MA
34 abstracts
Abstract
Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.Org: Flatiron Health, San Francisco, CA, Foundation Medicine, Inc., Cambridge, MA, Foundation Medicine Inc, Morrisville, NC, Flatiron Health, New York, NY, Flatiron Health, Dallas, TX,
Abstract
Practice- and provider-level inequities in next-generation sequencing (NGS) testing by race/ethnicity for patients (pts) with advanced non-small cell lung cancer (aNSCLC) treated in the community setting.Org: The West Cancer Center, OneOncology, Foundation Medicine, Inc., Cambridge, MA, Genentech Inc., Flatiron Health, San Francisco, CA,
Abstract
Walking dose required to achieve a clinically meaningful reduction in cancer-related fatigue among patients with breast cancer receiving chemotherapy: A URCC NCORP nationwide prospective cohort study.Org: James P. Wilmot Cancer Center, University of Rochester Medical Center, University of Rochester School of Medicine & Dentistry, University of Rochester, Providence Cancer Institute,
Abstract
Utility of circulating tumor DNA (ctDNA) to inform treatment of patients with metastatic breast cancer.Org: Foundation Medicine, Inc., Cambridge, MA, Allegheny Health Network Cancer Institute at Allegheny General Hospital, Weill Cornell Medicine, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD,
Abstract
Genomic alterations (GA) in ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) patients (pts) with metastatic breast cancer (MBC): Co-occurrence and prevalence along treatment course.Org: Foundation Medicine, Inc., Cambridge, MA, Winship Cancer Institute of Emory University,
Abstract
Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC).Org: Yale New Haven Hospital, New Haven, CT, Upstate University Hospital, Syracuse, NY, SUNY Upstate University Hospital,
Abstract
Pathological complete response (pCR) association with a novel homologous recombination deficiency HRD signature (HRDsig) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant therapy (Tx).Org: Cancer Center, Stanford, Palo Alto, CA, Foundation Medicine, Inc., San Diego, CA, Foundation Medicine, Inc., Cambridge, MA, SUNY Upstate Medical University, Syracuse, NY, Foundation Medicine, Inc., Boston, MA,
Abstract
Characterization of diverse targetable ERBB2 alterations in 512,993 patients with solid tumors.Org: Memorial Sloan Kettering Cancer Center, Foundation Medicine, Inc., Cambridge, MA,
Abstract
Genetic ancestry-associated differences in genomic profiling and treatment patterns in pancreatic ductal adenocarcinoma (PDAC).Org: Yale Cancer Center, Foundation Medicine, Inc., Cambridge, MA, Perlmutter Cancer Center, NYU Langone Health,
Abstract
Correlation of allele-specific HLA loss of heterozygosity in patients with cancer with driver mutations.Org: Affini-T Therapeutics, Inc., Foundation Medicine, Inc., Cambridge, MA, Memorial Sloan Kettering Cancer Center,
Abstract
Retrospective analysis of change in frequency of STK11 mutation in lung adenocarcinomas over a 10-year period.Org: SUNY Upstate Medical University, Foundation Medicine, Inc., Cambridge, MA,
Abstract
BRCA1/2 reversion mutations (BRCArev) in advanced prostate cancer in the absence of prior PARP inhibitor (PARPi) therapy.Org: Foundation Medicine, Inc., Cambridge, MA, Cedars-Sinai Medical Center, SUNY Upstate Medical University, University of California, San Diego Health,
Abstract
Prognostic value of baseline circulating tumor DNA (ctDNA) tumor fraction (TF) in metastatic hormone-sensitive prostate cancer (mHSPC).Org: Rogel Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, Foundation Medicine, Inc., Cambridge, MA, Cambridge, MA,
Abstract
Intimal sarcomas (ISarc) of the cardiac chambers (CC) of the heart and great vessels (GV): A comprehensive genomic profiling (CGP) study.Org: SUNY Upstate Medical University, Foundation Medicine, Inc., Cambridge, MA,
Abstract
Concordance between tissue (tumor DNA) and liquid (ctDNA) biopsy next-generation sequencing (NGS) data in detection of PIK3CA, AKT1, and PTEN alterations in breast cancer: A retrospective analysis.Org: Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, AstraZeneca, Gaithersburg, MD,
Abstract
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).Org: Yale School of Medicine, Foundation Medicine, Inc., Cambridge, MA, Foundation Medicine Inc, Morrisville, NC, Yale Cancer Center, Yale School of Medicine, New Haven, CT,
Abstract
Liquid-biopsy detection of FGFR2 and other actionable rearrangements in GI malignancies.Org: Weill Cornell Medicine and NewYork-Presbyterian Hospital, New York, NY, Englander Institute of Precision Medicine, New York Presbyterian Hospital, Foundation Medicine, Inc., Cambridge, MA, Vanderbilt University Medical Center,
Abstract
Characterization of diverse targetable alterations in ERBB2 and ERBB3 in 93,465 non-small cell lung cancers (NSCLC).Org: Memorial Sloan Kettering Cancer Center, Foundation Medicine, Inc., Cambridge, MA, University of California San Diego, Moores Cancer Center,
Abstract
Gynecologic-cancer analysis of ARID1A alterations detected in tissue and liquid biopsies.Org: Foundation Medicine, Inc., Cambridge, MA, National Cancer Institute, Vilnius, Lithuania,
Abstract
The effect of ctDNA tumor fraction (TF) on overall survival and concordance between tissue genomics and ctDNA in Lung-MAP.Org: Mount Sinai Health System, SWOG Statistics and Data Management Center, Seattle, WA, Fred Hutchinson Cancer Center/Division of Hematology and Oncology, Dana-Farber Cancer Institute, SWOG Statistical Center,
Abstract
Penile squamous cell carcinoma (PSCC) with elevated tumor mutational burden (TMB): A genomic landscape study.Org: H. Lee Moffitt Cancer Center and Research Institute, University of Washington; Fred Hutchinson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Vita-Salute San Raffaele University, Foundation Medicine, Inc., Cambridge, MA,
Abstract
Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.Org: Lifespan Health System, Providence, RI, Ohio State University Comprehensive Cancer Center, Columbus, OH, Yale Cancer Center, Yale School of Medicine, New Haven, CT,
Abstract
Effectiveness of PARP inhibitor maintenance therapy (mPARPi) in advanced ovarian cancer (OC) by BRCA1/2 and HRD signature in real-world practice.Org: Stephenson Cancer Center/University of Oklahoma Health Sciences Center and Sarah Cannon Research Institute, Sarah Cannon Research Institute/Tennessee Oncology, Foundation Medicine, Inc., Cambridge, MA, Stephenson Cancer Center at the University of Oklahoma HSC, University of Okahoma Health Sciences Center,
Abstract
Comprehensive genomic profiling (CGP) of clinically advanced and metastatic cutaneous adnexal carcinomas (CAs; MCADCA): A genomic landscape study.Org: SUNY Upstate Medical University, Upstate University Hospital, Foundation Medicine, Inc., Cambridge, MA,
Abstract
SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mechanisms of resistance to KRAS inhibitors.Org: Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Kras Kickers, GO2 Foundation for Lung Cancer, Addario Lung Cancer Medical Institute,
Abstract
Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness.Org: Foundation Medicine, Inc., Cambridge, MA, Mayo Clinic, Foundation Medicine Inc, Morrisville, NC,
Abstract
Circulating tumor DNA (ctDNA) monitoring to inform maintenance outcomes in patients (pts) with advanced NSCLC treated with induction atezolizumab+carboplatin+nab-paclitaxel (A+CnP).Org: H. Lee Moffitt Cancer Center and Research Institute, Foundation Medicine, Inc., Cambridge, MA, Genentech Inc., Natera, Inc., Genentech,
Abstract
CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS).Org: H. Lee Moffitt Cancer Center and Research Institute, Vita-Salute San Raffaele University, Saint Louis University Hospital, University of Washington; Fred Hutchinson Cancer Center, SUNY Upstate Medical University,
Abstract
Use of circulating tumor DNA (ctDNA) to complement tumor tissue homologous recombination repair (HRR) gene alteration testing in TALAPRO-2, a phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).Org: Peter MacCallum Cancer Centre, Melbourne, Australia, Institut Gustave Roussy, National Cancer Center Hospital East, Kashiwa, Japan, Auckland City Hospital and University of Auckland, Vall d’Hebron University Hospital/VHIO,
Abstract
Utility of ctDNA tumor fraction to inform negative liquid biopsy (LBx) results and need for tissue reflex in advanced non-small cell lung cancer (aNSCLC).Org: Foundation Medicine, Inc., Cambridge, MA, UC San Diego Moores Cancer Center,
Abstract
Clinical utility of liquid-based comprehensive genomic profiling (CGP) in gastrointestinal stromal tumors (GIST).Org: Boston Medical Center, Foundation Medicine, Inc., Cambridge, MA, Boston University Medical Campus, OHSU Knight Cancer Institute, Portland, OR,
Abstract
Outcomes of patients with advanced NF1-mutant melanoma treated with MEK inhibitors.Org: California Pacific Medical Center Research Institute, San Francisco, CA, San Francisco Department of Public Health, CanSino Biologics, Stockton Hematology/Oncology, Lodi,
Abstract
Programmed cell death ligand 1 (PD-L1) expression landscape and its relationship with tumor mutational burden (TMB) in a community-based cancer center patient population in rural central Nebraska.Org: Morrison Cancer Center Mary Lanning Healthcare, Hastings, NE, Foundation Medicine, Inc., Cambridge, MA, Morrison Cancer Center, Mary Lanning Healthcare, Hastings, NE, Morrison Cancer Center, Hastings, NE, Mary Lanning Healthcare, Hastings, NE,
Abstract
Negative selection of patients (pts) with HER2-positive and RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving dual HER2 blockade.Org: Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Memorial Sloan Kettering Cancer Center, New York, NY, USA, Department of Oncology, Veneto Institute of Oncology IOV - IRCCS, Padua, Italy, Padua, Italy, Padua, Italy,